Whitehawk Therapeutics (NASDAQ:WHWK) Announces Quarterly Earnings Results

Whitehawk Therapeutics (NASDAQ:WHWK) released its earnings results on Monday. The company reported ($0.23) earnings per share for the quarter, FiscalAI reports.

Whitehawk Therapeutics Price Performance

Shares of WHWK stock opened at $3.13 on Monday. Whitehawk Therapeutics has a one year low of $1.97 and a one year high of $5.49. The company’s fifty day moving average price is $3.68 and its 200-day moving average price is $3.83. The company has a market capitalization of $178.44 million, a price-to-earnings ratio of -2.79 and a beta of 0.99.

Analysts Set New Price Targets

Several research firms have recently commented on WHWK. Stifel Nicolaus assumed coverage on Whitehawk Therapeutics in a research note on Wednesday, September 30th. They issued a “buy” rating and a $9.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Whitehawk Therapeutics in a research report on Wednesday, September 2nd. Leerink Partners began coverage on Whitehawk Therapeutics in a research note on Monday, July 13th. They set an “outperform” rating and a $9.00 price objective for the company. Finally, Wall Street Zen raised shares of Whitehawk Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $8.33.

Institutional Investors Weigh In On Whitehawk Therapeutics

A number of institutional investors have recently bought and sold shares of WHWK. BlackRock Inc. bought a new stake in Whitehawk Therapeutics during the second quarter valued at about $8,807,000. ADAR1 Capital Management LLC bought a new position in shares of Whitehawk Therapeutics in the second quarter worth about $6,144,000. Montanova Capital LLC boosted its stake in shares of Whitehawk Therapeutics by 16.2% in the second quarter. Montanova Capital LLC now owns 4,300,000 shares of the company’s stock worth $19,694,000 after acquiring an additional 600,000 shares during the period. Bank of America Corp DE purchased a new stake in shares of Whitehawk Therapeutics during the second quarter worth about $159,000. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Whitehawk Therapeutics during the second quarter worth about $378,000. Hedge funds and other institutional investors own 52.08% of the company’s stock.

About Whitehawk Therapeutics

Whitehawk Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel medicines for the treatment of serious diseases. The company’s activities center on advancing an internal pipeline of therapeutic candidates through preclinical research and clinical development.

Whitehawk Therapeutics does not appear to have marketed products at this stage. Its work is focused primarily on research and development, including evaluating potential drug candidates for safety, efficacy and suitability for further clinical testing.

Publicly available information about the company’s specific pipeline, operating geographies and leadership is limited.